On July 18, 2025, Oppenheimer analyst Hartaj Singh announced an update regarding Sarepta Therapeutics (SRPT, Financial). The analyst has decided to maintain the company's "Outperform" rating. However, there has been a downward adjustment to the price target.
The new price target for Sarepta Therapeutics (SRPT, Financial) is set at $41.00 USD, down from the previous target of $45.00 USD. This represents a change of -8.89% in the price target.
Despite the adjusted price target, the "Outperform" rating suggests continued confidence in Sarepta Therapeutics (SRPT, Financial) and its future potential within the market. Investors are advised to consider this information as part of their investment strategy.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Sarepta Therapeutics Inc (SRPT, Financial) is $47.96 with a high estimate of $185.00 and a low estimate of $10.00. The average target implies an upside of 118.28% from the current price of $21.97. More detailed estimate data can be found on the Sarepta Therapeutics Inc (SRPT) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, Sarepta Therapeutics Inc's (SRPT, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $216.81, suggesting a upside of 886.85% from the current price of $21.97. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sarepta Therapeutics Inc (SRPT) Summary page.
